

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **Jinhai Medical Technology Limited**

**今海醫療科技股份有限公司**

*(Incorporated in the Cayman Islands with members’ limited liability)*

**(Stock Code: 2225)**

### **PROFIT WARNING**

This announcement is made by Jinhai Medical Technology Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the year ended 31 December 2024 (“**FY2024**”) and other information currently available to the Board, the Group is expected to record a loss after taxation of approximately S\$18.1 million as compared to a loss after taxation for year ended 31 December 2023 (“**FY2023**”) of approximately S\$4.1 million. Based on the unaudited consolidated management accounts of the Group for FY2024, the Board considered that the business of the Group demonstrated a steady development during FY2024. The Group expected to record revenue of approximately S\$50.2 million and gross profit of approximately S\$11.4 million for FY2024, as compared to revenue of approximately S\$45.6 million and gross profit of approximately S\$12.0 million for FY2023. The increase in net loss position for FY2024 was principally attributable to, amongst others, the increase in administrative expenses by approximately S\$15.9 million, primarily resulting from the incurrence of expenses on equity-settled share-based payments in the amount of approximately S\$13.3 million for FY2024, as a result of grant of share options to certain employees of the Group during FY2024 (FY2023: nil).

The Board wishes to remind the Shareholders and potential investors that the above is based on the draft unaudited consolidated management accounts of the Group for FY2024 and the information currently available to the Board. Such information has not been audited or reviewed by the auditors and the audit committee of the Company and is subject to adjustments upon further review. Shareholders and potential investors are advised to read carefully the annual results announcement of the Company for FY2024 which is expected to be published in March 2025.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Jinhai Medical Technology Limited**  
**Chen Guobao**  
*Chairman of the Board and Executive Director*

Hong Kong, 21 March 2025

*As at the date of this announcement, the Board comprises eight Directors, of which three are executive Directors, namely Mr. Chen Guobao, Mr. Wang Zhenfei, Mr. Li Yunping; two are non-executive Directors, namely Mr. Jiang Jiangyu and Mr. Wang Huasheng; and three are independent non-executive Directors, namely Mr. Yan Jianjun, Mr. Fan Yimin and Ms. Yang Meihua.*